NCT05266196View on ClinicalTrials.gov

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 15, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Ewing SarcomaMyxoid LiposarcomaDesmoplastic Small Round Cell TumorExtraskeletal Myxoid ChondrosarcomaAngiomatoid Fibrous HistiocytomaClear Cell SarcomaMyoepithelial TumorLow Grade Fibromyxoid SarcomaSclerosing Epithelioid Fibrosarcoma

Interventions

DRUG

Seclidemstat

Treatment assigned as per parent protocol

Trial Locations (1)

90403

Sarcoma Oncology Center, Santa Monica

All Listed Sponsors

lead

Salarius Pharmaceuticals, LLC

INDUSTRY